173 related articles for article (PubMed ID: 38503157)
1. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.
Mohan CD; Shanmugam MK; Gowda SGS; Chinnathambi A; Rangappa KS; Sethi G
Phytomedicine; 2024 Jun; 128():155379. PubMed ID: 38503157
[TBL] [Abstract][Full Text] [Related]
2. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
3. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
Feng Y; Thiagarajan PS; Ma PC
J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
Narayanankutty A
Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
[TBL] [Abstract][Full Text] [Related]
5. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
Whang YM; Jung SP; Kim MK; Chang IH; Park SI
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer.
Raj S; Kesari KK; Kumar A; Rathi B; Sharma A; Gupta PK; Jha SK; Jha NK; Slama P; Roychoudhury S; Kumar D
Mol Cancer; 2022 Jan; 21(1):31. PubMed ID: 35081970
[TBL] [Abstract][Full Text] [Related]
9. Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer.
Nisa L; Aebersold DM; Giger R; Zimmer Y; Medová M
Pharmacol Ther; 2014 Sep; 143(3):337-49. PubMed ID: 24786972
[TBL] [Abstract][Full Text] [Related]
10. Phytochemicals, withaferin A and carnosol, overcome pancreatic cancer stem cells as c-Met inhibitors.
Aliebrahimi S; Kouhsari SM; Arab SS; Shadboorestan A; Ostad SN
Biomed Pharmacother; 2018 Oct; 106():1527-1536. PubMed ID: 30119228
[TBL] [Abstract][Full Text] [Related]
11. Aberrant
Al-Ghabkari A; Huang B; Park M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
[TBL] [Abstract][Full Text] [Related]
12. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
13. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
14. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
15. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
Xu J; Liu S; Yang X; Cao S; Zhou Y
Life Sci; 2020 Dec; 263():118523. PubMed ID: 33039386
[TBL] [Abstract][Full Text] [Related]
16. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract][Full Text] [Related]
17. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
Liu D; Zhong M; Zhan D; Zhang Y; Liu S
Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
[TBL] [Abstract][Full Text] [Related]
18. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
[TBL] [Abstract][Full Text] [Related]
19. MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside.
Avan A; Maftouh M; Funel N; Ghayour-Mobarhan M; Boggi U; Peters GJ; Giovannetti E
Curr Med Chem; 2014; 21(8):975-89. PubMed ID: 23992325
[TBL] [Abstract][Full Text] [Related]
20. Targeting the c-MET signaling pathway for cancer therapy.
Liu X; Yao W; Newton RC; Scherle PA
Expert Opin Investig Drugs; 2008 Jul; 17(7):997-1011. PubMed ID: 18549337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]